CMC Reviewer Expectations for ANDAs Using QbD Approaches

Comprehensive Quality by Design in Pharmaceutical Development and Manufacture
2011 AIChE Annual Meeting
AIChE Annual Meeting
October 18, 2011 - 8:00pm

There has been an increase in science and risk-based approaches under the Quality by Design paradigm in new drug submissions to the FDA. There are particular challenges for generic drug manufacturers with respect to using QbD approaches, especially with more complex dosage forms, such as modified release (MR) products. In an effort to increase transparency with the generic industry and the pharmaceutical industry at large, this presentation will provide insight into CMC reviewer expectations when evaluating pharmaceutical development studies, the applicant’s process and product understanding, use of risk assessment tools, and proposed control strategies.
Professional Development Hours
0.5 PDHs
You will be able to download and print a certificate for these PDH credits once the content has been viewed. If you have already viewed this content, please click here to login.

Would you like to access this content?

No problem. You just have to complete the following steps.

You have completed 0 of 2 steps.

  1. Log in

    You must be logged in to view this content. Log in now.

  2. Purchase Technical Presentation

    You must purchase this technical presentation using one of the options below.
    If you already purchased this content recently, please click here to refresh the system's record of ownerships.


Credits 0.5 Use credits
List Price $25.00 Buy now
AIChE Members $15.00 Buy now
AIChE Undergraduate Student Members Free Free access
AIChE Graduate Student Members Free Free access
Skill Level: